Welcome to Helix Talk, a podcast presented by the Rosalm Franklin University College of Pharmacy.

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge.

This is an educational production, copyright Rosalind Franklin University of Medicine and Science.

This podcast contains general information for educational purposes only. This is not professional advice and should

not be used in lieu of obtaining advice from a qualified health care provider. And now, on to the show.

Welcome to episode 9 of Helix Talk. I'm your co-host Dr. Kane.

I'm Dr. Schumann. And I'm Dr. Patel.

And today we're talking about the evidence for the combination of an ACE inhibitor, an angiotensin receptor block, or an ARB, and

Aliskarin or Tecterno, which is a direct renin inhibitor.

So before we get into all this mumble, jumble, jumble, or drugs, let's talk about

what the renin system is all about.

Well, the first step in there is we look at the compound angiotensinogen, and this is something

that's produced in the liver, and then it's converted via renin to angiotensin 1.

It's actually some of the extra pieces, the peptides, are cleaved right off.

And as you might suspect,

eliskerin or tacturna is a direct renin inhibitor.

So this is where tacturna or eliskerin acts.

It inhibits this enzyme that converts angiotensinogen to angiotensin 1. And then eventually we need an enzyme called ACE that would convert angiotensin 1 to angiotensin 2.

So you can imagine our ACE inhibitors are going to block this step right here.

And then the final step once angiotensin 2 is produced is that it goes to the kidney

...